Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)-Reference-Cited by-同舟云学术

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

Published:2014-09-19 Issue:2 Volume:10 Page:277-286
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Donini M., ,Buti S.,Lazzarelli S.,Bozzetti R.,Rivoltini L.,Camisaschi C.,Castelli C.,Bearz A.,Simonelli C.,Lo Re G.,Mattioli R.,Caminiti C.,Passalacqua R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-014-0337-6.pdf

Reference37 articles.

1. Lilleby W, Fossa SD (2005) Chemotherapy in metastatic renal cell cancer. World J Urol 23:175–179

2. Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16(7–1516):7–15

3. Buti S, Brighenti M, Bongiovanni C et al (2007) Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer. J Immunother 30:780–786

4. Buzaid AC, Todd MB (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16(1):12–19

5. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolution of immune profiling: will there be a role for nanoparticles?;Nanoscale Horizons;2024

2. Special issue “The advance of solid tumor research in China”: Multi‐omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response;International Journal of Cancer;2022-06-18

3. Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies;Breast Care;2020

4. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications;Medical Oncology;2019-11-11

5. Liquid Biopsies and Cancer Immunotherapy;The Cancer Journal;2018-03